Oncology and Hematology - Global Oncology Academy

353-368 of 789

Obesity and Cancer Screening: National Trends and Disparities Revealed
Obesity and Cancer Screening: National Trends and Disparities Revealed
Clinician's Roundtable
Obesity and Cancer Screening: National Trends and Disparities Revealed
Vance Albaugh, MD, PhD
- Vance Albaugh, MD, PhD
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Charles Turck, PharmD, BCPS, BCCCP; Luhua (Michael) Wang, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Luhua (Michael) Wang, MD
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's Roundtable
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
David Feller-Kopman, MD
- David Feller-Kopman, MD
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and Hematology
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Paul L Swiecicki, MD
- Paul L Swiecicki, MD
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and Hematology
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and Hematology
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Yungan Tao
- Yungan Tao
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and Hematology
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Yungan Tao
- Yungan Tao
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and Hematology
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Prof. Markus Hecht
- Prof. Markus Hecht
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Project Oncology®
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Project Oncology®
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Project Oncology®
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Project Oncology®
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
MinuteCE®
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making  
James M. Cleary, MD, PhD
0.50 credits 4 episodes
- James M. Cleary, MD, PhD
0.50 credits 4 episodes

23/11